Cargando…

Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth

Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chiao-Yun, Lee, Li-Yu, Wang, Tzu-Hao, Hsu, Cheng-Lung, Tsai, Chia-Lung, Chao, Angel, Lai, Chyong-Huey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678831/
https://www.ncbi.nlm.nih.gov/pubmed/31330844
http://dx.doi.org/10.3390/cancers11071025
_version_ 1783441195254415360
author Lin, Chiao-Yun
Lee, Li-Yu
Wang, Tzu-Hao
Hsu, Cheng-Lung
Tsai, Chia-Lung
Chao, Angel
Lai, Chyong-Huey
author_facet Lin, Chiao-Yun
Lee, Li-Yu
Wang, Tzu-Hao
Hsu, Cheng-Lung
Tsai, Chia-Lung
Chao, Angel
Lai, Chyong-Huey
author_sort Lin, Chiao-Yun
collection PubMed
description Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acetate exerts synergistic antiproliferative effects against endometrial cancer cells. Treatment of cancer cells with palbociclib suppressed NPM/B23 phosphorylation at threonine 199 (Thr199). We further demonstrated that CDK6 acts as a NPM/B23 kinase. Palbociclib-induced NPM/B23 dephosphorylation sensitized endometrial cancer cells to megesterol acetate through the upregulation of ERα expression. Immunohistochemistry revealed an overexpression of phospho-NPM/B23 (Thr199) in human endometrial cancer, and phospho-NPM/B23 (Thr199) expression levels were inversely associated with Erα in clinical specimen. In a xenograft tumor model, the combination of palbociclib and megesterol acetate successfully inhibited tumor growth. Taken together, our data indicate that palbociclib promoted NPM/B23 dephosphorylation at Thr199—an effect mediated by disruption of CDK6 kinase activity. We conclude that palbociclib holds promise for the treatment of endometrial cancer when used in combination with megesterol acetate.
format Online
Article
Text
id pubmed-6678831
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66788312019-08-19 Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth Lin, Chiao-Yun Lee, Li-Yu Wang, Tzu-Hao Hsu, Cheng-Lung Tsai, Chia-Lung Chao, Angel Lai, Chyong-Huey Cancers (Basel) Article Endometrial cancer incidence rates are growing, especially in countries with rapid socioeconomic transitions. Despite recent advances in chemotherapy, hormone therapy, and targeted therapy, advanced/recurrent disease remains a clinical challenge. Palbociclib—a selective inhibitor of cyclin-dependent kinases (CDK) 4/6—has therapeutic potential against estrogen receptor (ER)-positive and HER2-negative breast cancer. However, the question as to whether it can be clinically useful in endometrial cancer remains open. Here, we show that combined treatment with palbociclib and megesterol acetate exerts synergistic antiproliferative effects against endometrial cancer cells. Treatment of cancer cells with palbociclib suppressed NPM/B23 phosphorylation at threonine 199 (Thr199). We further demonstrated that CDK6 acts as a NPM/B23 kinase. Palbociclib-induced NPM/B23 dephosphorylation sensitized endometrial cancer cells to megesterol acetate through the upregulation of ERα expression. Immunohistochemistry revealed an overexpression of phospho-NPM/B23 (Thr199) in human endometrial cancer, and phospho-NPM/B23 (Thr199) expression levels were inversely associated with Erα in clinical specimen. In a xenograft tumor model, the combination of palbociclib and megesterol acetate successfully inhibited tumor growth. Taken together, our data indicate that palbociclib promoted NPM/B23 dephosphorylation at Thr199—an effect mediated by disruption of CDK6 kinase activity. We conclude that palbociclib holds promise for the treatment of endometrial cancer when used in combination with megesterol acetate. MDPI 2019-07-20 /pmc/articles/PMC6678831/ /pubmed/31330844 http://dx.doi.org/10.3390/cancers11071025 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lin, Chiao-Yun
Lee, Li-Yu
Wang, Tzu-Hao
Hsu, Cheng-Lung
Tsai, Chia-Lung
Chao, Angel
Lai, Chyong-Huey
Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title_full Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title_fullStr Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title_full_unstemmed Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title_short Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth
title_sort palbociclib promotes dephosphorylation of npm/b23 at threonine 199 and inhibits endometrial cancer cell growth
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678831/
https://www.ncbi.nlm.nih.gov/pubmed/31330844
http://dx.doi.org/10.3390/cancers11071025
work_keys_str_mv AT linchiaoyun palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT leeliyu palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT wangtzuhao palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT hsuchenglung palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT tsaichialung palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT chaoangel palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth
AT laichyonghuey palbociclibpromotesdephosphorylationofnpmb23atthreonine199andinhibitsendometrialcancercellgrowth